Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by jimsenioron Apr 01, 2023 11:40am
266 Views
Post# 35373626

RE:Pharma faces looming patent cliff - seller's market in bio

RE:Pharma faces looming patent cliff - seller's market in bioUber on yahoo has posed a question to independent shareholders, and as I do not own a cell phone and one is required to join yahoo, I shall answer the question here.

The question: I would really love to know exactly what it would take to finally throw in the towel.

My answer: NOTHING.

My reasoning, and I do know I may be wrong.

This is not currently a pretty picture if one is just looking at the share price, and yes it does concern me, but not enough to throw in the towel. It is only by happenstance that we are still here at all. The Bernstein trial kept us in the game, and we regrouped and I dare say not elegantly at times. There does seem to be bots, so there is also that to consider.

I can only look at the science from a lay perspective. The following holds my interest.

The GOBLET trial from all four cohorts, especially the first look at Metastatic Colorectal Cancer.

The treatment of hematological malignancies, specifically the AMBUSH trial, and Dr. Craig Hofmeister and his RRMM plus opdivo trial.

Others will see different reasons for staying.

I believe in surviving.

                                                   OUTWIT
                                  OUTPLAY               OUTLAST

<< Previous
Bullboard Posts
Next >>